Welcome to our dedicated page for Biolife Solutions SEC filings (Ticker: BLFS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BioLife Solutions, Inc. (NASDAQ: BLFS) SEC filings page on Stock Titan provides access to the company’s official regulatory documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on BioLife’s activities as a developer and supplier of cell processing tools and services and bioproduction products and services for the cell and gene therapy (CGT) and broader biopharma markets.
Through periodic reports such as the Form 10-K annual report and Form 10-Q quarterly reports, investors can review disclosures on BioLife’s Cell Processing, Cold Chain, and Thawing product areas, its focus on biopreservation media and related tools, and the financial impact of divestitures and strategic transactions. These filings also describe the company’s use of GAAP and non-GAAP metrics, its presentation of discontinued operations related to divested subsidiaries, and other elements of its financial reporting framework.
Current reports on Form 8-K highlight specific material events, including quarterly earnings announcements, investor presentations, and the sale of its evo cold chain logistics subsidiary. Proxy materials such as the definitive proxy statement (DEF 14A) provide insight into corporate governance, board composition, executive compensation proposals, and matters submitted to stockholder votes at the annual meeting.
On Stock Titan, each new BioLife filing is captured from EDGAR and paired with AI-powered summaries that explain the key points in clear language. Users can quickly scan annual reports (Form 10-K), quarterly reports (Form 10-Q), and current reports (Form 8-K) to understand changes in BioLife’s cell processing business, portfolio evolution, and governance decisions. The filings page also surfaces information relevant to topics such as equity awards and compensation policies discussed in proxy statements, helping investors interpret the regulatory record behind the BLFS stock.
Mathew Aby J., EVP & Chief Scientific Officer of BioLife Solutions, Inc. (BLFS), reported a sale of company stock. The filing shows a sale of 630 shares of common stock on 09/11/2025 at a price of $26.83 per share executed under a Rule 10b5-1 trading plan established 03/08/2024 to satisfy tax withholding obligations arising from the vesting of restricted stock. After the reported sale, the reporting person beneficially owned 351,421 shares, held directly. The form is signed by the reporting person on 09/15/2025.
Troy Wichterman, Chief Financial Officer of BioLife Solutions, sold 1,032 shares of common stock on 09/11/2025 at $26.83 per share, reducing his direct holdings to 184,186 shares. The Form 4, signed 09/15/2025, states the sale was made under a Rule 10b5-1 trading plan established 03/08/2024 to cover tax withholding obligations tied to vesting restricted stock. No derivative transactions are reported.
Todd Berard, Chief Marketing Officer of BioLife Solutions, reported a sale of company stock on 09/11/2025. The Form 4 shows he disposed of 358 shares of common stock at a price of $26.83 per share under a Rule 10b5-1 trading plan adopted 03/08/2024 to satisfy tax withholding obligations tied to the vesting of restricted stock. After the transaction, Mr. Berard beneficially owned 133,906 shares directly. The filing is signed and dated 09/15/2025.
Sean Werner, Chief Technology Officer of BioLife Solutions, reported a sale of 72 shares of common stock on 09/11/2025 at $26.83 per share. After the sale he beneficially owns 26,312 shares (direct). The filing states the sale was executed under a Rule 10b5-1 trading plan adopted effective 09/01/2021 to satisfy tax withholding obligations tied to the vesting of restricted stock. The Form 4 is signed 09/15/2025.
BIOLIFE SOLUTIONS, INC. (BLFS) Rule 144 notice reports proposed sale of 714 common shares by a holder through Morgan Stanley Smith Barney on 09/15/2025 on NASDAQ, with an aggregate market value listed as $18,214.14 and total shares outstanding shown as 47,905,265. The securities were acquired as restricted stock units on 09/08/2025 from the issuer and the filing records payment or settlement on that same date.
The filer disclosed three prior sales by the same person in the past three months: 711 shares via a 10b5-1 sale on 06/16/2025 for $15,805.53, 198 shares on 07/07/2025 for $4,409.46, and 219 shares on 08/26/2025 for $5,571.36. The filing includes a representation that the seller is not aware of undisclosed material adverse information and notes the option to rely on a 10b5-1 plan; no plan adoption date or signature block details are present in the provided content.
Insider sale under pre-existing plan: Aby J. Mathew, EVP & Chief Scientific Officer of BioLife Solutions, reported a sale of 531 shares of BioLife common stock on 08/26/2025 at a price of $25.44 per share. The sale was made pursuant to a Rule 10b5-1(c) trading plan adopted on 02/24/2022 to satisfy tax withholding obligations arising from the vesting of restricted stock. After the reported sale, the filing shows Mr. Mathew beneficially owns 352,051 shares directly. The Form 4 was signed on 08/28/2025 and the filer indicated the transaction was executed under the 10b5-1 plan.
Karen A. Foster, Chief Quality and Operations of BioLife Solutions Inc. (BLFS), reported a sale of 413 shares of the company's common stock on 08/26/2025 at a price of $25.44 per share. Following the transaction, Ms. Foster beneficially owns 194,183 shares, held directly.
The filing states the sale was executed under a Rule 10b5-1(c) trading plan adopted by the reporting person on 02/24/2022 to satisfy tax withholding obligations related to the vesting of restricted stock. The Form 4 is signed and dated 08/28/2025.
Sean Werner, Chief Technology Officer of BioLife Solutions, sold 111 shares of the company's common stock on 08/26/2025 at $25.44 per share under a pre-existing Rule 10b5-1(c) trading plan. The Form 4 shows the sale was to satisfy tax withholding obligations tied to the vesting of restricted stock and the reporting person retained 26,384 shares of common stock after the transaction. The filing is signed by Sean Werner on 08/28/2025 and indicates the Form is filed by one reporting person.
Insider sale under 10b5-1 plan: Troy Wichterman, Chief Financial Officer of BioLife Solutions, sold 590 shares of BioLife Solutions Inc. (BLFS) on 08/26/2025 at a price of $25.44 per share. After the sale, Mr. Wichterman beneficially owned 185,218 shares, held directly. The filing states the sale was executed pursuant to a Rule 10b5-1(c) trading plan adopted on 02/24/2022 to satisfy tax withholding obligations arising from the vesting of restricted stock. The Form 4 is signed by the reporting person on 08/28/2025.
Sarah Aebersold, Chief Human Resources Officer of BioLife Solutions, sold 219 shares of common stock on 08/26/2025 at $25.44 per share under a pre-established Rule 10b5-1(c) plan. The filing states the sale was executed to satisfy tax withholding obligations arising from the vesting of restricted stock. After the reported transaction, the reporting person beneficially owned 78,304 shares of BioLife Solutions common stock, held directly.
The sale was made pursuant to a 10b5-1 trading plan adopted 02/24/2022, which the filer checked on the form to indicate pre-planned execution; the Form 4 is signed and dated 08/28/2025.
FAQ
What is the current stock price of Biolife Solutions (BLFS)?
What is the market cap of Biolife Solutions (BLFS)?
